Journal
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021
Volume 61, Issue -, Pages 65-84Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-030920-025745
Keywords
pharmacogenomics; pharmacogenetics; clinical implementation; adverse drug reaction; drug safety; drug effectiveness
Categories
Ask authors/readers for more resources
The clinical implementation of pharmacogenetic biomarkers is growing as new genetic variants associated with drug outcomes are discovered. Incorporating pharmacogenetic information into healthcare improves drug safety and reduces empiricism in drug selection. However, barriers to the implementation of pharmacogenetic testing remain.
The clinical implementation of pharmacogenetic biomarkers continues to grow as new genetic variants associated with drug outcomes are discovered and validated. The number of drug labels that contain pharmacogenetic information also continues to expand. Published, peer-reviewed clinical practice guidelines have also been developed to support the implementation of pharmacogenetic tests. Incorporating pharmacogenetic information into health care benefits patients as well as clinicians by improving drug safety and reducing empiricism in drug selection. Barriers to the implementation of pharmacogenetic testing remain. This review explores current pharmacogenetic implementation initiatives with a focus on the challenges of pharmacogenetic implementation and potential opportunities to overcome these challenges.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available